Quoin Pharmaceuticals, Ltd. Stock Prediction and Forecast [QNRX]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 17 Sept 2025, 03:28 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Quoin Pharmaceuticals, Ltd. Stock Prediction and Forecast [QNRX]](https://i.ytimg.com/vi/y_2_hSn-J9Y/hqdefault.jpg)
AI-generated source summary
The analysis indicates that Quoin Pharmaceuticals (QNRX) has been ranked as a buy candidate since September 12, 2025, with a score of 3.8. The stock has gained approximately 7.98% since then, averaging a 2.66% daily return. The stock has broken its short-term falling trend, indicating a potential trend shift upwards. Support is expected at $7.90, potentially offering a second buy opportunity. According to fan theory, the next peak level is $10.08. The three-month trend suggests a potential change of -20.42% with a possible return between -44.59% and -23.4%. The 12-month analysis anticipates a 201.98% change, putting the future price between $18.22 and $48.75. The latest daily update shows a green day with a 4.94% gain to $8.21. Analyst ratings suggest a strong sell on return on equity and a neutral position for price to book value.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
